The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
M | Musculo-skeletal system | |
2
|
M01 | Antiinflammatory and antirheumatic products | |
3
|
M01C | Specific antirheumatic agents | |
4
|
M01CB | Gold preparations | |
5
|
M01CB03 | Auranofin |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Code | Route | Amount | Notes |
|---|---|---|---|
| ORAL | Oral | 6 mg |
| Active Ingredient |
|---|
|
Auranofin is an orally available compound, used to treat rheumatoid arthritis, with anti-inflammatory activities. The main mechanism of action of auranofin is through the inhibition of reduction/oxidation (redox) enzymes such as thioredoxin reductase (TrxR). The thiol ligand contained in auranofin has a high affinity for thiol and selenol groups, to which it forms stable, and irreversible, adducts. Redox enzymes such as TrxR are essential to many cellular processes, particularly in maintaining the intracellular levels of reactive oxygen species (ROS). |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.